Ethic Inc. Has $21.85 Million Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Ethic Inc. grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 13.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 42,002 shares of the medical research company's stock after purchasing an additional 5,066 shares during the period. Thermo Fisher Scientific comprises 0.4% of Ethic Inc.'s portfolio, making the stock its 29th largest holding. Ethic Inc.'s holdings in Thermo Fisher Scientific were worth $21,851,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Principal Financial Group Inc. boosted its stake in shares of Thermo Fisher Scientific by 22.1% during the 3rd quarter. Principal Financial Group Inc. now owns 1,247,838 shares of the medical research company's stock worth $771,876,000 after acquiring an additional 225,568 shares in the last quarter. First Hawaiian Bank boosted its position in Thermo Fisher Scientific by 3.0% during the fourth quarter. First Hawaiian Bank now owns 4,158 shares of the medical research company's stock worth $2,163,000 after purchasing an additional 122 shares during the period. Hudson Valley Investment Advisors Inc. ADV boosted its position in Thermo Fisher Scientific by 1.3% during the fourth quarter. Hudson Valley Investment Advisors Inc. ADV now owns 20,331 shares of the medical research company's stock worth $10,577,000 after purchasing an additional 268 shares during the period. Wealth Enhancement Advisory Services LLC boosted its position in Thermo Fisher Scientific by 0.7% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 126,603 shares of the medical research company's stock worth $65,863,000 after purchasing an additional 887 shares during the period. Finally, CCM Investment Advisers LLC boosted its position in Thermo Fisher Scientific by 9.7% during the fourth quarter. CCM Investment Advisers LLC now owns 31,921 shares of the medical research company's stock worth $16,606,000 after purchasing an additional 2,822 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO traded down $7.85 during midday trading on Friday, reaching $402.93. 2,318,607 shares of the company traded hands, compared to its average volume of 1,799,554. The firm has a market cap of $152.10 billion, a PE ratio of 24.38, a PEG ratio of 2.99 and a beta of 0.82. The stock's 50-day simple moving average is $464.67 and its 200-day simple moving average is $514.56. Thermo Fisher Scientific Inc. has a 12 month low of $401.75 and a 12 month high of $627.88. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. The business had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Thermo Fisher Scientific's revenue for the quarter was up .2% on a year-over-year basis. During the same period in the prior year, the company earned $5.11 EPS. As a group, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were paid a $0.43 dividend. The ex-dividend date was Friday, March 14th. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.43%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.09%.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on TMO. Wells Fargo & Company decreased their target price on Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating for the company in a research report on Thursday, April 24th. Barclays reduced their price objective on Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating for the company in a research report on Thursday, April 10th. Stifel Nicolaus reduced their price objective on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a research report on Thursday, April 24th. Scotiabank reduced their price objective on Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating for the company in a research report on Friday, April 25th. Finally, Evercore ISI reduced their price objective on Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a research report on Thursday, April 24th. Five investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and a consensus target price of $607.43.

Insider Activity

In related news, SVP Michael A. Boxer sold 3,775 shares of Thermo Fisher Scientific stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the sale, the senior vice president now directly owns 10,816 shares in the company, valued at $5,759,736.32. This trade represents a 25.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total value of $5,166,700.00. Following the completion of the sale, the chief executive officer now owns 115,174 shares of the company's stock, valued at approximately $59,506,950.58. The trade was a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 14,075 shares of company stock worth $7,305,942. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.